<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855712</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-05-2008</org_study_id>
    <nct_id>NCT00855712</nct_id>
  </id_info>
  <brief_title>Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation</brief_title>
  <acronym>PROCEEDII</acronym>
  <official_title>Prospective, Multicenter, Randomized, Clinical Investigation of TransMedics Organ Care System (OCS) for Cardiac Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newark Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera S. Maria della Misericordia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare survival of both patients and newly transplanted
      hearts following heart transplantation among patients who were transplanted with donated
      hearts preserved on ice and those who were transplanted with donated hearts using the Organ
      Care System (OCS). The Organ care system preserves the hearts in a warm blood perfused
      beating state. The study also compares the number of rejection episodes, heart related
      adverse events, ICU time, and ventilation time between the two groups. The study is
      considered a success if survival in the OCS group was not inferior to the ice group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day patient survival following transplantation with the originally transplanted heart and no mechanical circulatory assist device at day 30</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all cardiac graft-related serious adverse events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven ISHLT grade 2R or 3R acute rejection on any of the surveillance endomyocardial biopsies or clinically symptomatic rejection requiring augmentation of immunosuppressive therapy during the 30 day follow up</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Organ Care System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold cardioplegia solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Organ Care System</intervention_name>
    <description>The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.</description>
    <arm_group_label>Organ Care System</arm_group_label>
    <other_name>OCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cold Cardioplegia Solution</intervention_name>
    <description>This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital</description>
    <arm_group_label>Cold cardioplegia solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Recipient Day of Transplant

          -  Registered male or female primary heart transplant candidate

          -  â‰¥18 years old

          -  Signed, written informed consent document and authorization to use and disclose
             protected health information

        Donor Hearts

          -  &lt;60 years old

          -  Mean systolic blood pressure &gt;60 mmHg at the time of final heart assessment

          -  Satisfactory echocardiography assessment defined as:

          -  Ejection fraction &gt;40%

          -  Absence of severe segmental wall motion abnormalities

          -  Absence of left ventricular hypertrophy (inter ventricular septum and posterior wall
             thickness &lt;1.3 cm)

          -  Absence of valve abnormalities (trace to mild valvular regurgitation is acceptable)

        Exclusion Criteria:

        Recipient Day of Transplant

          -  &gt;4 previous sternotomies

          -  Chronic renal failure as defined by chronic serum creatinine &gt;3.0 mg/dL for more than
             2 weeks and/or requiring hemodialysis (except for hemodialysis or hemofiltration for
             fluid overload)

          -  Ventilator dependence at the time of transplant

          -  Use of a ventricular assist device for &gt; 30 days and the presence of any of the
             following: sepsis, intracranial hemorrhage or heparin induced thrombocytopenia

          -  Panel reactive antibodies &gt; 40% with a positive prospective cross match and/or virtual
             cross match

          -  Use of an investigational drug or device, other than OCS, during the study.

          -  Simultaneous transplant of non-heart allograft, except for concurrent kidney
             transplant

        Donor Hearts

          -  Abnormal coronary angiogram defined as &gt;50% stenosis, requiring coronary bypass

          -  Donor-to-recipient body weight ratio of &lt;0.6

          -  Inotrope support at time of final heart assessment including, but not limited to:

               -  Dopamine &gt;10 ug/kg/min

               -  Dobutamine &gt; 10 ug/kg/min

               -  Milrinone &gt;0.3 ug/kg/min

               -  Epinephrine &gt; 0.03 ug/kg/min

               -  Norepinephrine &gt; 0.03 ug/kg/min

               -  Any bolus dose of the above prior to explants that would result in exceeding the
                  above stated criteria

          -  Presence of any exclusion criterion based on the standard practice of the
             investigational site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abbas Ardehali, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harefield Hospital</name>
      <address>
        <city>London Borough of Hillingdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2009</study_first_posted>
  <disposition_first_submitted>May 11, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 3, 2015</disposition_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Transplant</keyword>
  <keyword>Warm Perfusion</keyword>
  <keyword>Organ Care</keyword>
  <keyword>Resting Mode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cardioplegic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

